

Accepted Manuscript

Emerging role of IL-35 in inflammatory autoimmune diseases

Lin-Chong Su, Xiao-Yan Liu, An-Fang Huang, Wang-Dong Xu



PII: S1568-9972(18)30106-X
DOI: doi:[10.1016/j.autrev.2018.01.017](https://doi.org/10.1016/j.autrev.2018.01.017)
Reference: AUTREV 2160

To appear in:

Received date: 8 January 2018
Accepted date: 15 January 2018

Please cite this article as: Lin-Chong Su, Xiao-Yan Liu, An-Fang Huang, Wang-Dong Xu , Emerging role of IL-35 in inflammatory autoimmune diseases. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Autrev(2018), doi:[10.1016/j.autrev.2018.01.017](https://doi.org/10.1016/j.autrev.2018.01.017)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Emerging role of IL-35 in inflammatory autoimmune diseases

Lin-Chong Su^{1,2}, Xiao-Yan Liu³, An-Fang Huang^{4*}, Wang-Dong Xu^{3**}

¹Department of Rheumatology and Immunology, Affiliated Minda Hospital of Hubei Institute for Nationalities, 2 Wufengshan Road, Enshi, Hubei, 445000, P.R. China.

²Hubei Provincial Key Laboratory of Occurrence and Intervention of Rheumatic diseases, Affiliated Minda Hospital of Hubei Institute for Nationalities, 2 Wufengshan Road, Enshi, Hubei, 445000, P.R. China.

³Department of Evidence-Based Medicine, School of Public Health, Southwest Medical University, 1 Xianglin Road, Luzhou, Sichuan, 646000, P.R. China.

⁴Department of Rheumatology and Immunology, the Affiliated Hospital of Southwest Medical University, 25 Taiping Road, Luzhou, Sichuan, 646000, P.R. China.

*Corresponding author at: Department of Rheumatology and Immunology, the Affiliated Hospital of Southwest Medical University, 25 Taiping Road, Luzhou, Sichuan, 646000, P.R. China. E-mail address: 980829791@qq.com

**Corresponding author at: Department of Evidence-Based Medicine, School of Public Health, Southwest Medical University, 1 Xianglin Road, Luzhou, Sichuan, 646000, P.R. China. E-mail address: loutch123@163.com, Phone: +86 (830) 3175813, Fax: +86 (830) 3175823

Abstract

Interleukin 35 (IL-35) is the recently identified member of the IL-12 family of cytokines and provides the possibility to be a target for new therapies for autoimmune, inflammatory diseases. It is composed of an α chain (p35) and a β chain (EBI3). IL-35 mediates signaling by binding to its receptors, activates subsequent signaling pathways, and therefore, regulates the differentiation, function of T, B cells, macrophages, dendritic cells. Recent findings have shown abnormal expression of IL-35 in inflammatory autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, type 1 diabetes, psoriasis, multiple sclerosis, autoimmune hepatitis, experimental autoimmune uveitis. In addition, functional analysis suggested that IL-35 is critical in the onset and development of these diseases. Therefore, the present study will systematically review what had been occurred regarding IL-35 in inflammatory autoimmune disease. The information collected will help to understand the biologic role of IL-35 in immune cells, and give information about the therapeutic potential of IL-35 in

Download English Version:

<https://daneshyari.com/en/article/8736354>

Download Persian Version:

<https://daneshyari.com/article/8736354>

[Daneshyari.com](https://daneshyari.com)